Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Colchicine is an orally administered, potent antiinflammatory medication that is indicated for the treatment of gout and pericarditis. METHODS: We performed a randomized, double-blind trial involving patients recruited within 30 days after a myocardial infarction. The patients were randomly assigned to receive either low-dose colchicine (0.5 mg once daily) or placebo. The primary efficacy end point was a composite of death from cardiovascular causes, resuscitated cardiac arrest, myocardial infarction, stroke, or urgent hospitalization for angina leading to coronary revascularization. The components of the primary end point and safety were also assessed. RESULTS: A total of 4745 patients were enrolled; 2366 patients were assigned to the colchicine group, and 2379 to the placebo group. Patients were followed for a median of 22.6 months. The primary end point occurred in 5.5% of the patients in the colchicine group, as compared with 7.1% of those in the placebo group (hazard ratio, 0.77; 95% confidence interval [CI], 0.61 to 0.96; P = 0.02). The hazard ratios were 0.84 (95% CI, 0.46 to 1.52) for death from cardiovascular causes, 0.83 (95% CI, 0.25 to 2.73) for resuscitated cardiac arrest, 0.91 (95% CI, 0.68 to 1.21) for myocardial infarction, 0.26 (95% CI, 0.10 to 0.70) for stroke, and 0.50 (95% CI, 0.31 to 0.81) for urgent hospitalization for angina leading to coronary revascularization. Diarrhea was reported in 9.7% of the patients in the colchicine group and in 8.9% of those in the placebo group (P = 0.35). Pneumonia was reported as a serious adverse event in 0.9% of the patients in the colchicine group and in 0.4% of those in the placebo group (P = 0.03). CONCLUSIONS: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials have shown that targeted inhibition of this inflammatory pathway, as measured by changes in CRP concentrations, can reduce the rate of cardiovascular events.5, 6, 7”
From Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials (2023) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was also not an isolated finding as a similar reduction of CVD risk linked to reduction of inflammation was reported in the COLCOT trial when participants were given low‐dose colchicine (a standard anti‐inflammatory drug) (Tardif et al., 2019).”
From Treatment of periodontitis and C ‐reactive protein: A systematic review and meta‐analysis of randomized clinical trials (2023) · cites this paper as Tardif et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reduction in LDL-C has been strongly associated with improved cardiovascular outcomes, and 3 recent trials have demonstrated favorable effects with anti-inflammatory therapies.[21][22][23][24]”
From Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredIn the citing paper
“However, when appraised together, the evidence supports apolipoprotein B as being necessary for lipid-mediated atherogenesis by LDL-C to occur. 57,58 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [58]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
Ravelli, R. B. G., Gigant, B., Curmi, P. A., Jourdain, I., Lachkar, S., Sobel, A., & Knossow, M. (2004) · Nature · doi:10.1038/nature02393 · Cited by 1,630
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Self-citationLow-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.10.027 · Cited by 1,054
Semiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Cited by
Items 101–200 of 1,006
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 192
Hilgendorf, I., Frantz, S., & Frangogiannis, N. G. (2024) · Circulation Research · doi:10.1161/circresaha.124.323658 · Cited by 180
“457 Thus, colchicine has become the first guideline-recommended anti-inflammatory medication in cardiovascular secondary prevention.”
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2025) · JACC · doi:10.1016/j.jacc.2025.08.047 · Cited by 177
Direct oral anticoagulants: evidence and unresolved issues
Chan, N., Sobieraj-Teague, M., & Eikelboom, J. W. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32439-9 · Cited by 189
NLRP3 inflammasome as a key driver of vascular disease
Takahashi, M. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab010 · Cited by 188
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Stewart, S., Yang, K. C. K., Atkins, K., Dalbeth, N., & Robinson, P. C. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-2120-7 · Cited by 180
Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction
Mewton, N., Roubille, F., Bresson, D., Prieur, C., Bouleti, C., Bochaton, T., Ivanes, F., Dubreuil, O., Biere, L., Hayek, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056177 · Cited by 179
Self-citationThe role of efferocytosis‐fueled macrophage metabolism in the resolution of inflammation
Schilperoort, M., Ngai, D., Sukka, S. R., Avrampou, K., Shi, H., & Tabas, I. (2023) · Immunological Reviews · doi:10.1111/imr.13214 · Cited by 170
“105 Cardioprotective actions were also found for canakinumab, a monoclonal antibody against IL-1 β , which reduces the risk of atherosclerotic cardiovascular disease in patients with previous myocardial infarction.”
BackgroundSex and Gender Differences in Heart Failure
Regitz-Zagrosek, V. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0004 · Cited by 174
Inflammation Resolution: Implications for Atherosclerosis
Doran, A. C. (2022) · Circulation Research · doi:10.1161/circresaha.121.319822 · Cited by 163
Targeting the CCL2–CCR2 axis for atheroprotection
Georgakis, M. K., Bernhagen, J., Heitman, L. H., Weber, C., & Dichgans, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac094 · Cited by 170
Neutrophil counts and cardiovascular disease
Luo, J., Thomassen, J. Q., Nordestgaard, B. G., Tybjærg-Hansen, A., & Frikke-Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad649 · Cited by 167
“Several trials implementing pharmaceutical anti-inflammatory therapies have yielded promising results, including canakinumab targeting interleukin (IL)-1 β , 1 colchicine targeting microtubules, 2,3 and ziltivekimab targeting the IL-6 ligand.”
BackgroundImmunometabolic control of trained immunity
Riksen, N. P., & Netea, M. G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100897 · Cited by 167
“effective in reducing future cardiovascular events (Ridker et al., 2017; Tardif et al., 2019).”
Pyroptosis is a critical immune-inflammatory response involved in atherosclerosis
He, X., Fan, X., Bai, B., Lu, N., Zhang, S., & Zhang, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105447 · Cited by 169
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a)
Zhang, W., Speiser, J. L., Ye, F., Tsai, M. Y., Cainzos-Achirica, M., Nasir, K., Herrington, D. M., & Shapiro, M. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.016 · Cited by 169
Baldini, C., Moriconi, F. R., Galimberti, S., Libby, P., & De Caterina, R. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab447 · Cited by 167
Targeting the Inflammasome in Cardiovascular Disease
Olsen, M. B., Gregersen, I., Sandanger, Ø., Yang, K., Sokolova, M., Halvorsen, B. E., Gullestad, L., Broch, K., Aukrust, P., & Louwe, M. C. (2022) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2021.08.006 · Cited by 167
“9 y, median Reduced ischemic cardiovascular events Increased risk of pneumonia Tardif et al (38)”
BackgroundShared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease
Weber, B. N., Giles, J. T., & Liao, K. P. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00969-7 · Cited by 164
Risk Factor Burden and Long‐Term Prognosis of Patients With Premature Coronary Artery Disease
Zeitouni, M., Clare, R. M., Chiswell, K., Abdulrahim, J., Shah, N., Pagidipati, N. P., Shah, S. H., Roe, M. T., Patel, M. R., & Jones, W. S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017712 · Cited by 164
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., Bradwin, G., Hasan, A. A., & Rifai, N. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa160 · Cited by 161
“Very recently, the COLCOT trial has shown that antiinflammatory therapy with colchicine can also reduce vascular events, a finding of interest as this microtubule inhibitor may also have impact on the NLRP3 inflammasome and hence downstream production of both IL-6 and hsCRP.(18) From a diagnostic perspective, as IL-6…”
ResultThe Anti-Inflammatory Effect of Taurine on Cardiovascular Disease
Qaradakhi, T., Gadanec, L. K., McSweeney, K. R., Abraham, J. R., Apostolopoulos, V., & Zulli, A. (2020) · Nutrients · doi:10.3390/nu12092847 · Cited by 161
“Targeting the inflammatory cascade during CVD is expanding rapidly, as demonstrated by clinical trials involving anti-inflammatory agents [71].”
BackgroundInflammation in heart failure: pathophysiology and therapeutic strategies
Boulet, J., Sridhar, V. S., Bouabdallaoui, N., Tardif, J., & White, M. (2024) · Inflammation Research · doi:10.1007/s00011-023-01845-6 · Cited by 200
“Specifically, colchicine has been clearly demonstrated in two large, randomized trials (COLCOT and LoDoCo2) to be beneficial in reducing the risk of atherothrombotic CV events in patients with coronary artery disease [112, 113].”
BackgroundSelf-citationThe anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
Perricone, C., Triggianese, P., Bartoloni, E., Cafaro, G., Bonifacio, A. F., Bursi, R., Perricone, R., & Gerli, R. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102468 · Cited by 159
“Its mechanisms of actions are through the inhibition of tubulin polymerization and microtubule generation and, possibly, effects on cellular adhesion molecules, inflammatory chemokines, and the inflammasome [190, 191] .”
Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach
Nigrovic, P. A., Lee, P. Y., & Hoffman, H. M. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.017 · Cited by 174
Kelly, P. J., Lemmens, R., Weimar, C., Walsh, C., Purroy, F. F., Barber, M., Collins, R., Cronin, S., Członkowska, A., Desfontaines, P., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00968-1 · Cited by 181
Coronary heart disease and atrial fibrillation: a vicious cycle
Liang, F., & Wang, Y. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00702.2020 · Cited by 181
Pacinella, G., Ciaccio, A. M., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415722 · Cited by 202
C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease
Burger, P. M., Koudstaal, S., Mosterd, A., Fiolet, A. T. L., Teraa, M., van der Meer, M. G., Cramer, M. J., Visseren, F. L. J., Ridker, P. M., Dorresteijn, J. A. N., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.035 · Cited by 184
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Reyes, A. Z., Hu, K. A., Teperman, J., Muskardin, T. W., Tardif, J., Shah, B., & Pillinger, M. H. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-219174 · Cited by 171
Self-citationFrancisco, J. J., & Re, D. P. D. (2023) · Antioxidants · doi:10.3390/antiox12111944 · Cited by 191
Trends in Cardiogenic Shock Complicating Acute Myocardial Infarction
Aïssaoui, N., Puymirat, É., Delmas, C., Ortuno, S., Durand, É., Bataille, V., Drouet, É., Bonello, L., Bonnefoy‐Cudraz, E., Lesmeles, G., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1750 · Cited by 151
“002 Glycoprotein IIb/IIIa inhibitors 18 (33) 38 (31) 18 (27) 15 (27) 9 (24) 14 (21) 0.”
Gaba, P., Gersh, B. J., Muller, J. E., Narula, J., & Stone, G. W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00769-8 · Cited by 174
Novel mechanisms and therapeutic targets in atherosclerosis: inflammation and beyond
Weber, C., Habenicht, A. J. R., & von Hundelshausen, P. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad304 · Cited by 165
Opstal, T. S. J., Hoogeveen, R. M., Fiolet, A. T. L., Silvis, M. J. M., The, S. H. K., Bax, W. A., de Kleijn, D. P. V., Mosterd, A., Stroes, E. S. G., & Cornel, J. H. (2020) · Circulation · doi:10.1161/circulationaha.120.050560 · Cited by 150
Libby, P. (2021) · Cells · doi:10.3390/cells10040951 · Cited by 167
“The large-scale COLCOT trial in patients enrolled soon after an acute coronary syndrome showed a reduction in recurrent major adverse cardiovascular events including revascularization [41].”
BackgroundAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“Dyslipidemia and vascular inflammation Recent human CVD outcome trials using IL-1β antibodies (75) or colchicine (76) have demonstrated reduced CVD.”
BackgroundAutoimmune diseases and atherosclerotic cardiovascular disease
Porsch, F., & Binder, C. J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01045-7 · Cited by 163
Ridker, P. M., Lei, L., Louie, M. J., Haddad, T. M., Nicholls, S. J., Lincoff, A. M., Libby, P., Nissen, S. E., & on behalf of the CLEAR Outcomes Investigators (2023) · Circulation · doi:10.1161/circulationaha.123.066213 · Cited by 168
“…data, crucial to the development of the inflammation hypothesis of atherothrom-bosis, eventually led to clinical trials demonstrating that anti-inflammatory agents such as canakinumab 3 and low-dose colchicine 4,5 can substantially reduce cardio-vascular event rates without changing LDLC.”
BackgroundSignaling pathways in macrophages: molecular mechanisms and therapeutic targets
Li, M., Wang, M., Wen, Y., Zhang, H., Zhao, G., & Gao, Q. (2023) · MedComm · doi:10.1002/mco2.349 · Cited by 189
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Nissen, S. E., Menon, V., Nicholls, S. J., Brennan, D., Laffin, L., Ridker, P., Ray, K. K., Mason, D., Kastelein, J. J. P., Cho, L., et al. (2023) · JAMA · doi:10.1001/jama.2023.9696 · Cited by 146
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review
Zhang, F.-S., He, Q.-Z., Qin, C. X., Little, P. J., Weng, J., & Xu, S. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00835-w · Cited by 170
“In the later sections, we will address the clinical trials of colchicine, including the LoDoCo, LoDoCo2, and COLCOT trials.”
BackgroundInfluentialLow-Grade Chronic Inflammation: a Shared Mechanism for Chronic Diseases
Cifuentes, M., Verdejo, H., Castro, P., Corvalán, A. H., Ferreccio, C., Quest, A. F. G., Kogan, M. J., & Lavandero, S. (2024) · Physiology · doi:10.1152/physiol.00021.2024 · Cited by 203
Deftereos, S. G., Siasos, G., Γιαννόπουλος, Γ., Vrachatis, D. A., Angelidis, C., Giotaki, S. G., Gargalianos, P., Giamarellou, H., Gogos, C., Daikos, G. L., et al. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.03.002 · Cited by 152
“Beyond these, colchicine has been administered in numerous research protocols with various clinical settings (including acute myocardial infarction) showing a favorable safety profile and promising results 3, 4 .”
BackgroundInflammation and cardiovascular diseases: lessons from seminal clinical trials
Liberale, L., Montecucco, F., Schwarz, L., Lüscher, T. F., & Camici, G. G. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa211 · Cited by 163
Dib, L. H., Koneva, L. A., Edsfeldt, A., Zurke, Y.-X., Sun, J., Nitulescu, M., Attar, M., Lutgens, E., Schmidt, S., Lindholm, M., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00295-x · Cited by 170
“The highest degree of connectivity was observed between the C1Q, HMOX1, TREM2hi and PLIN2hi/TREM1hi populations.”
BackgroundMethodInfluentialPugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac133 · Cited by 144
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis
Leiva, O., AbdelHameid, D., Connors, J. M., Cannon, C. P., & Bhatt, D. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.08.011 · Cited by 155
“Colchicine is another anti-inflammatory drug studied in patients with chronic CAD and in post-MI populations (28,29).”
BackgroundUnderstanding the molecular mechanisms of statin pleiotropic effects
German, C. A., & Liao, J. K. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03492-6 · Cited by 177
Single Cell RNA Sequencing in Atherosclerosis Research
Williams, J. W., Winkels, H., Durant, C. P., Zaitsev, K., Ghosheh, Y., & Ley, K. F. (2020) · Circulation Research · doi:10.1161/circresaha.119.315940 · Cited by 151
Colchicine in COVID-19: an Old Drug, New Use
Schlesinger, N., Firestein, B. L., & Brunetti, L. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00225-6 · Cited by 151
Vaidya, K., Tucker, B., Kurup, R., Khandkar, C., Pandžić, E., Barraclough, J., Machet, J., Misra, A., Kavurma, M. M., Martínez, G., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018993 · Cited by 146
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 234
Challenges and advances in the management of inflammation in atherosclerosis
Xing, Y., & Lin, X. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.016 · Cited by 162
SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress
Chang, R. P., Mamun, A., Dominic, A., & Le, N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.605908 · Cited by 147
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics
He, L., Zhang, C., Chen, Q., Wang, L., & Huang, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108152 · Cited by 151
A bibliometric analysis of T cell and atherosclerosis
Wei, N., Xu, Y., Li, Y., Shi, J., Zhang, X., You, Y., Sun, Q., Zhai, H., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948314 · Cited by 156
“trial of non-specific anti-inflammatory treatment with methotrexate (60), and the cardiovascular outcome test of colchicine (61, 62) all exhibited anti-inflammatory effects.”
BackgroundCrosstalk Between Macrophages and Vascular Smooth Muscle Cells in Atherosclerotic Plaque Stability
Yurdagul, A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316233 · Cited by 145
Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications
Zhang, H., Yang, K., Chen, F., Liu, Q., Ni, J., Cao, W., Hua, Y., He, F., Liu, Z., Li, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975367 · Cited by 134
Amezcua-Castillo, E., González‐Pacheco, H., Martín, A. S.-S., Méndez-Ocampo, P., Gutiérrez-Moctezuma, I., Massó, F., Sierra‐Lara, D., Springall, R., Rodríguez, E., Arias‐Mendoza, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11092444 · Cited by 163
“Neither acetylsalicylic acid nor colchicine reduces CRP levels [66,67].”
Bulluck, H., Paradies, V., Barbato, E., Baumbach, A., Bøtker, H. E., Capodanno, D., Caterina, R. D., Cavallini, C., Davidson, S. M., Feldman, D. N., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab271 · Cited by 142
“HEB was funded by the Novo Nordisk Foundation (grant numbers NNF14OC0013337, NNF15OC0016674), The Danish Council for Strategic Research (11-108354), and Trygfonden (109624).”
Immunometabolic mechanisms of heart failure with preserved ejection fraction
Schiattarella, G. G., Alcaide, P., Condorelli, G., Gillette, T. G., Heymans, S. R. B., Jones, E. A. V., Kallikourdis, M., Lichtman, A. H., Marelli‐Berg, F. M., Shah, S. J., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00032-w · Cited by 143
Lin, A., Nerlekar, N., Yuvaraj, J., Fernandes, K., Jiang, C., Nicholls, S. J., Dey, D., & Wong, D. T. L. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa224 · Cited by 145
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 206
Small, A., Pournamdari, A. B., Melloni, G. E. M., Scirica, B. M., Bhatt, D. L., Raz, I., Braunwald, E., Giugliano, R. P., Sabatine, M. S., Peloso, G. M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5605 · Cited by 143
Recent Development in Therapeutic Cardiac Patches
Mei, X., & Cheng, K. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.610364 · Cited by 132
Robinson, P. C., Terkeltaub, R. A., Pillinger, M. H., Shah, B., Karalis, V. D., Karatza, E., Liew, D. F. L., Imazio, M., Cornel, J. H., Thompson, P. L., et al. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.07.025 · Cited by 127
Trained immunity in atherosclerotic cardiovascular disease
Riksen, N. P., Bekkering, S., Mulder, W. J. M., & Netea, M. G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00894-y · Cited by 150
“In patients at high risk of ASCVD, treatment with the anti-IL-1β antibody canakinumab 1 or with the anti-inflammatory drug colchicine lowered the risk of major adverse cardiovascular events compared with placebo 2,3 .”
BackgroundNicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 331
Trained Immunity: An Underlying Driver of Inflammatory Atherosclerosis
Zhong, C., Yang, X., Feng, Y., & Yu, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00284 · Cited by 134
“Recent intervention trials that reduced inflammation showed significantly improved cardiovascular outcomes among patients at cardiovascular risk (6, 7), further demonstrating the causal role for inflammation in atherosclerotic cardiovascular disease (ASCVD).”
BackgroundImmune cell profiling in atherosclerosis: role in research and precision medicine
Fernandez, D. M., & Giannarelli, C. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00589-2 · Cited by 137
Animal Models of Atherosclerosis–Supportive Notes and Tricks of the Trade
Gisterå, A., Ketelhuth, D. F. J., Malin, S., & Hansson, G. K. (2022) · Circulation Research · doi:10.1161/circresaha.122.320263 · Cited by 138
World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update
Laranjo, L., Lanas, F. T., Sun, M. C., Chen, D. A., Hynes, L., Imran, T. F., Kazi, D. S., Kengne, A. P., Komiyama, M., Kuwabara, M., et al. (2024) · Global Heart · doi:10.5334/gh.1278 · Cited by 168
van Diemen, P. A., Bom, M. J., Driessen, R. S., Schumacher, S. P., Everaars, H., de Winter, R. W., van de Ven, P. M., Freiman, M., Goshen, L., Heijtel, D., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.02.026 · Cited by 128
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Choi, H. K., McCormick, N., & Yokose, C. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00725-9 · Cited by 134
Zhou, Y., Xu, Z., & Liu, Z. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.910908 · Cited by 146
Endothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis
Chen, P., Schwartz, M. A., & Simons, M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00053 · Cited by 125
“Low-dose colchicine showed some survival benefit in patients with recent myocardial infarction in COLCOT trial, but whether this is due to antiplaque effects has not been examined (33).”
BackgroundBatra, G., Ghukasyan Lakic, T., Lindbäck, J., Held, C., White, H. D., Stewart, R. A. H., Koenig, W., Cannon, C. P., Budaj, A., Hagström, E., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3079 · Cited by 117
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Konwerski, M., Gąsecka, A., Opolski, G., Grabowski, M., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11030355 · Cited by 118
“The benefits of adding colchicine to standard therapy were also shown in COLCOT study, which included patients with a history of MI within the last month [243].”
MethodGarcía‐Escobar, A., Vera, S., Márquez, D. T., Santana, B. R., y, A. J.-R., Jiménez‐Valero, S., Galeote, G., Cabrera, J. Á., & Moreno, R. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104598 · Cited by 151
Puri, R., Nissen, S. E., Arsenault, B. J., John, J. S., Riesmeyer, J. S., Ruotolo, G., McErlean, E. S., Menon, V., Cho, L., Wolski, K., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2413 · Cited by 126
Yu, M., Yang, Y., Dong, S., Zhao, C., Yang, F., Yuan, Y.-F., Liao, Y.-H., He, S.-L., Liu, K., Wei, F., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069808 · Cited by 132
“8 Anti-inflammatory treatment with colchicine leads to a more significant reduction in the risk of major adverse cardiovascular and cerebrovascular events compared with the lipid-lowering treatment with PCSK9i, which is consistent with the more significant changes in minimum FCT caused by…”
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
Ridker, P. M., Tuttle, K. R., Perkovic, V., Libby, P., & MacFadyen, J. G. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac444 · Cited by 117
IL-6 and Cardiovascular Risk: A Narrative Review
Mehta, N. N., deGoma, E. M., & Shapiro, M. D. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01259-7 · Cited by 153
“…evidence from human genetic [9–13], epidemiological [14, 15], and mechanistic [16, 17], studies as well as results of canakinumab [18, 19] and colchicine [20, 21] trials support the therapeutic potential of IL-6 pathway inhibition to lower the risk of CVD independent of traditional risk factors.”
Wallentin, L., Eriksson, N., Olszowka, M., Grammer, T. B., Hagström, E., Held, C., Kleber, M. E., Koenig, W., März, W., Stewart, R. A. H., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003513 · Cited by 116
Chronic low‐grade inflammation in heart failure with preserved ejection fraction
Mesquita, T., Lin, Y., & Ibrahim, A. G.-E. (2021) · Aging Cell · doi:10.1111/acel.13453 · Cited by 128
“Colchicine was recently shown to decrease cardiovascular- related mortality in patients after myocardial infarction (Tardif et al., 2019).”
BackgroundInflammation in Coronary Microvascular Dysfunction
Sagris, M., Theofilis, P., Antonopoulos, A. S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., & Tousoulis, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413471 · Cited by 115
“Cholesterol crystals are present through all stages of atherosclerosis and can activate the NLRP3 inflammasome within these inflammatory cells to produce IL-1β and IL-18, key mediators in the inflammatory cascade that drive plaque progression and instability [6].”
BackgroundZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts
Enzan, N., Matsushima, S., Ikeda, S., Okabe, K., Ishikita, A., Yamamoto, T., Sada, M., Miyake, R., Tsutsui, Y., Nishimura, R., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.322227 · Cited by 125
Inflammatory Mediators of Endothelial Dysfunction
Dri, E., Lampas, E., Lazaros, G. A., Lazarou, E., Theofilis, P., Tsioufis, C. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13061420 · Cited by 162
Ridker, P. M. (2020) · Circulation · doi:10.1161/circulationaha.119.045256 · Cited by 111
ANDREOU, A., Trantza, S., Filippou, D., Sipsas, N. V., & Tsiodras, S. (2020) · In Vivo · doi:10.21873/invivo.11946 · Cited by 130
Satny, M., Hubacek, J. A., & Vrablík, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00977-6 · Cited by 134
The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications
Wang, X., Chen, L., Wei, J., Zheng, H., Zhou, N., Xu, X., Deng, X., Liu, T., & Zou, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02220-z · Cited by 148
Silvis, M. J. M., Demkes, E. J., Fiolet, A. T. L., Dekker, M., Bosch, L., van Hout, G. P. J., Timmers, L., & de Kleijn, D. P. V. (2021) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10049-w · Cited by 112
Samuel, M., Tardif, J.-C., Bouabdallaoui, N., Khairy, P., Dubé, M.-P., Blondeau, L., & Guertin, M.-C. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.10.006 · Cited by 112
Self-citationInflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease
Cainzos‐Achirica, M., Glassner, K. L., Hassan, S. Z., Dey, A. K., Agrawal, T., Quigley, E. M. M., Abraham, B. P., Acquah, I., Yahya, T., Mehta, N. N., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.027 · Cited by 131
Systemic lupus erythematosus and cardiovascular disease
Frostegård, J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13557 · Cited by 139
Oikonomou, E. K., Leopoulou, M., Theofilis, P., Antonopoulos, A. S., Siasos, G., Latsios, G., Mystakidi, V. C., Antoniades, C. A., & Tousoulis, D. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.027 · Cited by 124
Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis
Hettwer, J., Hinterdobler, J., Miritsch, B., Deutsch, M.-A., Li, X., Mauersberger, C., Moggio, A., Braster, Q., Gram, H., Robertson, A. A. B., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab337 · Cited by 111
Batta, A., Hatwal, J., Batta, A., Verma, S., & Sharma, Y. P. (2023) · World Journal of Cardiology · doi:10.4330/wjc.v15.i5.229 · Cited by 126
Metadata
- Authors
- Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., Berry, C., López-Sendón, J., Ostadal, P., Koenig, W., Angoulvant, D., Grégoire, J. C., Lavoie, M.-A., Dubé, M.-P., Rhainds, D., Provencher, M., Blondeau, L., Orfanos, A., L’Allier, P. L., Guertin, M.-C., & Roubille, F.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From the Montreal Heart Institute (J.-C.T., R.I., J.C.G., M.-A.L., M.-P.D., D.R., P.L.L.) and the Montreal Health Innovations Coordinating Center (M.P., L.B., A.O., M.-C.G.), Montreal, Centre Hospitalier Régional de Lanaudière, Joliette (S.K.), and Institut de Cardiologie et Pneumologie de Québec, Quebec City (O.F.B.) — all in Canada; San Francisco General Hospital, San Francisco (D.D.W.); Estudios Clínicos Latinoamérica, Rosario, Argentina (R.D.); Associazione Nazionale Medici Cardiologi...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-12-26
- Volume
- 381
- Issue
- 26
- Pages
- 2497-2505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2986700515
- Cited by
- 3,159
- References
- 20
- Citations by year
- 2026: 505 · 2025: 519 · 2024: 445 · 2023: 415 · 2022: 414 · 2021: 485 · 2020: 361 · 2019: 10
- FWCI
- 230.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- Government of Quebec
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- colchicine, myocardial infarction, anti-inflammatory therapy, inflammation in atherosclerosis, cardiovascular mortality, major adverse cardiovascular events, stroke, angina pectoris, diarrhea, pneumonia, drug safety, low-dose colchicine, secondary prevention, coronary revascularization, cardiac arrest, myocardial infarction recurrence, cardiovascular risk reduction, cost-effectiveness, quality of life
- MeSH terms
- Aged, Angina Pectoris, Anti-Inflammatory Agents, C-Reactive Protein, Cardiovascular Diseases, Colchicine, Double-Blind Method, Female, Humans, Male, Middle Aged, Myocardial Infarction, Recurrence, Biomarkers, Incidence, Proportional Hazards Models, Stroke, Kaplan-Meier Estimate, Intention to Treat Analysis, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

